264 related articles for article (PubMed ID: 12138191)
1. Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3.
Kumar A; Zhao Y; Meng G; Zeng M; Srinivasan S; Delmolino LM; Gao Q; Dimri G; Weber GF; Wazer DE; Band H; Band V
Mol Cell Biol; 2002 Aug; 22(16):5801-12. PubMed ID: 12138191
[TBL] [Abstract][Full Text] [Related]
2. Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator.
Zeng M; Kumar A; Meng G; Gao Q; Dimri G; Wazer D; Band H; Band V
J Biol Chem; 2002 Nov; 277(47):45611-8. PubMed ID: 12235159
[TBL] [Abstract][Full Text] [Related]
3. hAda3 degradation by papillomavirus type 16 E6 correlates with abrogation of the p14ARF-p53 pathway and efficient immortalization of human mammary epithelial cells.
Shamanin VA; Sekaric P; Androphy EJ
J Virol; 2008 Apr; 82(8):3912-20. PubMed ID: 18256148
[TBL] [Abstract][Full Text] [Related]
4. Human ADA3 binds to estrogen receptor (ER) and functions as a coactivator for ER-mediated transactivation.
Meng G; Zhao Y; Nag A; Zeng M; Dimri G; Gao Q; Wazer DE; Kumar R; Band H; Band V
J Biol Chem; 2004 Dec; 279(52):54230-40. PubMed ID: 15496419
[TBL] [Abstract][Full Text] [Related]
5. Identification of a peptide that disrupts hADA3-E6 interaction with implications in HPV induced cancer therapy.
Chand V; Kapoor A; Kundu S; Nag A
Life Sci; 2022 Jan; 288():120157. PubMed ID: 34801511
[TBL] [Abstract][Full Text] [Related]
6. PKN binds and phosphorylates human papillomavirus E6 oncoprotein.
Gao Q; Kumar A; Srinivasan S; Singh L; Mukai H; Ono Y; Wazer DE; Band V
J Biol Chem; 2000 May; 275(20):14824-30. PubMed ID: 10809724
[TBL] [Abstract][Full Text] [Related]
7. Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.
Kehmeier E; Rühl H; Voland B; Stöppler MC; Androphy E; Stöppler H
Virology; 2002 Jul; 299(1):72-87. PubMed ID: 12167343
[TBL] [Abstract][Full Text] [Related]
8. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300.
Zimmermann H; Degenkolbe R; Bernard HU; O'Connor MJ
J Virol; 1999 Aug; 73(8):6209-19. PubMed ID: 10400710
[TBL] [Abstract][Full Text] [Related]
9. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.
Crook T; Tidy JA; Vousden KH
Cell; 1991 Nov; 67(3):547-56. PubMed ID: 1657399
[TBL] [Abstract][Full Text] [Related]
10. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins.
Park JS; Kim EJ; Lee JY; Sin HS; Namkoong SE; Um SJ
Int J Cancer; 2001 Mar; 91(6):822-7. PubMed ID: 11275986
[TBL] [Abstract][Full Text] [Related]
11. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
Mansur CP; Marcus B; Dalal S; Androphy EJ
Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus type 77 E6 protein selectively inhibits p53-dependent transcription of proapoptotic genes following UV-B irradiation.
Giampieri S; García-Escudero R; Green J; Storey A
Oncogene; 2004 Jul; 23(34):5864-70. PubMed ID: 15077176
[TBL] [Abstract][Full Text] [Related]
13. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
Scheffner M; Werness BA; Huibregtse JM; Levine AJ; Howley PM
Cell; 1990 Dec; 63(6):1129-36. PubMed ID: 2175676
[TBL] [Abstract][Full Text] [Related]
14. The ING4 Binding with p53 and Induced p53 Acetylation were Attenuated by Human Papillomavirus 16 E6.
Guo Y; Meng X; Wang Q; Wang Y; Shang H
PLoS One; 2013; 8(8):e71453. PubMed ID: 23967213
[TBL] [Abstract][Full Text] [Related]
15. Papillomavirus E6 PDZ interactions can be replaced by repression of p53 to promote episomal human papillomavirus genome maintenance.
Brimer N; Vande Pol SB
J Virol; 2014 Mar; 88(5):3027-30. PubMed ID: 24352452
[TBL] [Abstract][Full Text] [Related]
16. The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation.
Gao Q; Srinivasan S; Boyer SN; Wazer DE; Band V
Mol Cell Biol; 1999 Jan; 19(1):733-44. PubMed ID: 9858596
[TBL] [Abstract][Full Text] [Related]
17. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation.
Li X; Coffino P
J Virol; 1996 Jul; 70(7):4509-16. PubMed ID: 8676476
[TBL] [Abstract][Full Text] [Related]
18. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53.
Hoppe-Seyler F; Butz K
J Virol; 1993 Jun; 67(6):3111-7. PubMed ID: 8388491
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage.
Kessis TD; Slebos RJ; Nelson WG; Kastan MB; Plunkett BS; Han SM; Lorincz AT; Hedrick L; Cho KR
Proc Natl Acad Sci U S A; 1993 May; 90(9):3988-92. PubMed ID: 8387205
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumour suppressor gene proteins in oesophageal cancer.
Agarwal SK; Chatterji A; Bhambhani S; Sharma BK
Indian J Exp Biol; 1998 Jun; 36(6):559-63. PubMed ID: 9731468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
